Degradation of Fluoroquinolone Antibiotics and Identification of Metabolites/Transformation Products by LC-MS/MS by Maia, Alexandra S. et al.
HPLC 2013  
Amsterdam 
 
39th International Symposium on 
High Performance Liquid Phase 
Separations and Related Techniques 
16-20 June 2013 
 
 





ENVI14_TU Degradation of Fluoroquinolone Antibiotics and Identification of 
Metabolites/Transformation Products by LC-MS/MS 
 Alexandra S Maia
1
, Ana R Ribeiro
2
, Catarina L Amorim
3
, Juliana C Barreiro
4
, Quezia B 
Cass
4
, Paula ML Castro
5





CICS-ISCSN-CESPU, CBQF-ESB-UCP, Gandra - Paredes, PT; 
2
CICS-ISCSN-CESPU, CBQF-ESB-
UCP, CEQUIMED-UP, Gandra - Paredes, PT; 
3
CBQF-ESB-UCP, CEQUIMED-UP, Porto, PT; 
4
DQ-UFSCar, São Carlos - SP, BR; 
5
CBQF/ESB-UCP, Porto, PT; 
6
CICS-ISCSN-CESPU, 
CEQUIMED-UP, Gandra - Paredes, PT 
  
Abstract: Antibiotics are a therapeutic class widely found in environmental matrices and 
extensively studied due to its persistence and implications for multi-resistant bacteria 
development. Degradation of four fluoroquinolone antibiotics, namely Ofloxacin (OFL), 
Norfloxacin (NOR), Ciprofloxacin (CPF) and Moxifloxacin (MOX), at 10 mg L-1 using a 
mixed bacterial culture, was assessed for 60 days. The assays were followed by a 
developed and validated analytical method of HPLC with Fluorescence Detection using a 
Luna PFP (2) 3µm column. The optimized conditions allowed picturing 
metabolites/transformation products formation and accumulation during the process, 
stating an incomplete mineralization, also shown by fluoride release. OFL and MOX 
presented the highest (98.3%) and the lowest (80.5%) extent of degradation after 19 days 
of assay, respectively. Some of these intermediate compounds were identified by LC-
MS/MS in selected degradation samples. Most of the intermediates were already 
described as biodegradation and/or photodegradation products in different conditions, 
but new and/or unknown metabolites were also present. 
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